Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL593 phase 1/2 study in healthy adults and participants with GRN-associated frontotemporal dementia
NL-OMON59411Phase 2Not yet recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Feb 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of DNL593 in frontotemporal dementia (FTD) (3 arms), sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence, severity, and seriousness of treatment-emergent adverse events and Change from baseline in safety assessments. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
DNL593
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON59411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59411.